

88. (New) The method of any of claims 86 or 87, wherein the hyperproliferative cell is a cancer cell.

Q 2 cont

89. (New) The method of claim 88, wherein the cancer cell is selected from the group consisting of a colorectal cell, a head and neck cancer cell, a breast cancer cell, a liver cancer cell and a gastric cancer cell.

II. REMARKS

Claims 2 to 55 are canceled without prejudice or disclaimer. Claims 56 to 89 are added. Accordingly, claims 1 and 56 to 89 are pending in the subject application. Support for the newly added claims is found in the original claims as filed, and in the specification which supports these claims. No new matter is added by these amendments and entry thereof is respectfully requested.

The subject application is a continuation of U.S. Serial No. 09/235,961, in which the Examiner indicated allowable subject matter. The non-allowed claims were canceled in that application without prejudice or disclaimer and are under continued examination herein.

If a telephone interview would advance prosecution of the subject application, the Examiner is invited to telephone the undersigned at the number provided below.

In the unlikely event that the transmittal letter is separated from this document and/or the Patent Office determines that an extension and/or other relief is required, Applicants petition for any required relief including extensions of time and authorize the Assistant

Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 50-0974**, referencing Attorney Docket No. 126745200402. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Respectfully submitted,

Date: February 12, 2001

By: 

Antoinette F. Konski
Reg. No. 34,202

Baker & McKenzie
660 Hansen Way
Palo Alto, California 94304
Telephone: (650) 856-2400
Facsimile: (650) 856-9299